Accelerated Protein Biomarker Discovery from FFPE tissue samples using Single-shot, Short Gradient Microflow SWATH MS

Rui Sun^{1,2*}, Christie Hunter^{3*#}, Chen Chen⁴, Weigang Ge^{1,2}, Nick Morrice³, Shuang Liang^{1,2}, Chunhui Yuan^{1,2}, Qiushi Zhang^{1,2}, Xue Cai^{1,2}, Xiaoyan Yu⁵, Lirong Chen⁵, Shaozheng Dai⁶, Zhongzhi Luan⁶, Ruedi Aebersold^{7,8}, Yi Zhu^{1,2#}, Tiannan Guo^{1,2#}

1, Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, 18 Shilongshan Road, Hangzhou 310024, Zhejiang Province, China

2, Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, 18 Shilongshan Road, Hangzhou 310024, Zhejiang Province, China

3, SCIEX, USA and UK (NM)

4, SCIEX, China

5, Department of Pathology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310009, China

6, School of Computer Science and Engineering, Beihang University, Beijing, China

7, Department of Biology, Institute of Molecular Systems Biology, ETH Zurich, Switzerland

8, Faculty of Science, University of Zurich, Zurich, Switzerland

* co-first

co-correspondence

Emails:

Christie Hunter: christie.hunter@sciex.com

Yi Zhu: zhuyi@westlake.edu.cn

Tiannan Guo: guotiannan@westlake.edu.cn

27 **ABSTRACT (no more than 4000 characters)**

28 We report and evaluated a microflow, single-shot, short gradient SWATH MS method
 29 intended to accelerate the discovery and verification of protein biomarkers in clinical
 30 specimens. The method uses 15-min gradient microflow-LC peptide separation, an optimized
 31 SWATH MS window configuration and OpenSWATH software for data analysis.

32

33 We applied the method to a cohort 204 of FFPE prostate tissue samples from 58 prostate
 34 cancer patients and 10 prostatic hyperplasia patients. Altogether we identified 27,976
 35 proteotypic peptides and 4,043 SwissProt proteins from these 204 samples. Compared to a
 36 reference SWATH method with 2-hour gradient the accelerated method consumed only 27%
 37 instrument time, quantified 80% proteins and showed reduced batch effects. 3,800 proteins
 38 were quantified by both methods in two different instruments with relatively high consistency
 39 ($r = 0.77$). 75 proteins detected by the accelerated method with differential abundance
 40 between clinical groups were selected for further validation. A shortlist of 134 selected
 41 peptide precursors from the 75 proteins were analyzed using MRM-HR, exhibiting high
 42 quantitative consistency with the 15-min SWATH method ($r = 0.89$) in the same sample set.
 43 We further verified the capacity of these 75 proteins in separating benign and malignant
 44 tissues (AUC = 0.99) in an independent prostate cancer cohort (n=154).

45

46 Overall our data show that the single-shot short gradient microflow-LC SWATH MS method
 47 achieved about 4-fold acceleration of data acquisition with reduced batch effect and a
 48 moderate level of protein attrition compared to a standard SWATH acquisition method.
 49 Finally, the results showed comparable ability to separate clinical groups.

50

51

52 **Keywords:** SWATH MS; Data-independent Acquisition; FFPE; Biomarker; Prostate cancer

53

54 INTRODUCTION

55 A large number of clinical and pre-clinical research questions require biomarkers for the
56 classification of samples or phenotypes. Because they are thought to closely reflect the
57 biochemical state of samples, protein biomarkers are particularly valuable. Protein biomarkers
58 have been intensely sought to indicate disease type or stage, to report disease progression or
59 response or resistance to treatment. For the most part protein biomarker projects use mass
60 spectrometry as the base technique. In spite of enormous research efforts, the number of
61 protein biomarkers discovered by proteomic methods that have progressed to clinical utility
62 remains small (1-4).

63 Protein biomarker discovery and validation projects face significant technical and
64 logistical challenges, including the following: i) biological protein abundance variability.
65 Useful protein biomarkers will only be discovered if the variability within a population is
66 smaller than the variability between protein groups. In the context of a twin cohort study of
67 plasma proteins we have shown that the variability of proteins and the root cause for the
68 variability varies greatly in a human population and that particularly variable proteins are
69 unlikely to be selected as biomarkers (5). ii) confounding effects. Protein biomarker studies
70 suffer from a range of confounding effects, including batch effects of sample collection,
71 sample processing, data acquisition and data analysis. Batch effects are particularly severe
72 among different cohorts that might be required to validate results from a discovery cohort, iii)
73 sample availability. Frequently, sample cohorts of sufficient size and quality to generate
74 sufficient statistical power are not available and iv) technical limitations. Even if suitable
75 cohorts are available acquiring reproducible protein patterns by mass spectrometry from
76 extended cohorts has been costly and challenging. For example, typically, protein biomarkers
77 have multi-dimensional fractionation of the peptides generated from digested, tissue-extracted
78 proteins followed by the analysis of the fractions by shotgun MS analysis. Even if isotopic or
79 isobaric labeling methods increase the multiplexing capability of such analyses (6), the
80 general approach remains expensive and technically challenging (7-9). Overall, these
81 challenges convincingly support the need for the proteomic measurement of large sample
82 cohorts at moderate cost, limited batch effects and high degree of reproducibility. At present
83 state-of-the art, large scale clinical proteomic studies consist of 100 to 200 clinical samples
84 (9-11) and there are indication, *e.g* the lack of stability of discovered marker panels that
85 suggest that this number of samples is at the lower end of the required size range(12). Further,
86 these studies were for the most part carried out by highly specialized groups or consortia
87 using highly optimized analytical platforms. For many proteomic research groups that lack
88 the means to implement the involved consortia methods, meaningful protein biomarker
89 studies have therefore remained out of reach. Therefore, there is an urgent need for robust,
90 highly reproducible, high throughput methods that support large-scale biomarker studies at
91 moderate cost and with limited time consumption.

92 Sample throughput can be increased with short LC gradients for the separation of
93 peptides. Bekker-Jensen et.al have combined multiple dimension pre-fractionation with
94 relatively short LC gradient using shotgun proteomics to achieve deep proteome analysis (13);
95 however, this approach lacks reproducibility and it is still time-consuming for a large cohort
96 study. We and others have found that SWATH/DIA mass spectrometry (14) is a more suitable
97 acquisition method to classify samples in large sample cohorts(5, 15-17). SWATH/DIA is an
98 acquisition method for biomarker studies because it identifies and quantifies peptide
99 precursors via peak groups consisting of fragment ion chromatograms from highly convoluted
100 mass spectra (15) and thus obviates the need to isolate peptide precursors during acquisition.
101 This improves data completeness and enables efficient single-shot proteomic analysis. The
102 key to this MS technique is the ability to collect high-resolution MS/MS spectra at very high
103 acquisition rates, such that a wide mass range can be covered with a series of smaller Q1
104 isolation windows in an LC compatible cycle time. Thus the fast scanning rate of TripleTOF
105 system has been the key in enabling the shortening of LC gradients for analyzing complex
106 tissue proteomes, from 120 min (15) to 45 min (17) without strongly compromising proteome

depth, and has been increasingly applied to analyze various types of clinical samples including plasma (5) and tumor tissues (15, 17, 18). A faster nano-LC and Orbitrap-based MS method has been reported recently to allow analysis of plasma and cell line samples using a 21-min gradient (19). However, this method requires specialized LC system.

To further improve the robustness and throughput of the proteomic analysis of sizable sample cohorts, the use of microflow chromatography is a promising option. An increasing number of studies have demonstrated the applicability of microflow coupled with SWATH MS (20-24). E.g. the Ralser group applied microflow-LC and SWATH to study yeast proteome at a throughput of 60 samples per day (24).

Here, we established and optimized a 15-min gradient microflow LC SWATH method, and rigorously examined its performance by analyzing 204 FFPE prostate tissue samples. From the detected 4,043 proteins we prioritized 75 that were further verified with respect to their ability to separate cancer from hyperplasia in an independent FFPE prostate tissue sample cohort study by complementary methods. The results indicate that short gradient microflow-LC SWATH is a suitable and robust method for clinical protein biomarker studies.

EXPERIMENTAL PROCEDURES

Standard protein digests

Digests of proteins isolated from HEK 293 cell were prepared as previously described (25) and provided by Dr Yansheng Liu from ETH Zurich (now in Yale University). Protein digests from K562 cells were obtained from the SWATH Performance Kit (SCIEX). 10% (v/v) iRT peptides (Biognosys, Switzerland) were spiked into peptide samples prior to MS analysis for retention time calibration.

PCa patient cohorts and formalin-fixed paraffin-embedded (FFPE) samples

Two prostate cancer (PCa) sample cohorts termed PCZA and PCZB were used in this study. The PCZA was acquired by the Second Affiliated Hospital College of Medicine, Zhejiang University and consisted of 58 PCa patients and 10 benign prostatic hyperplasia (BPH) patients. The PCZB cohort was acquired by the Second Affiliated Hospital College of Medicine, Zhejiang University and consisted of 24 PCa patients and 30 BPH patients whose benign and hyperplastic regions have been distinguished. All patients were recruited in 2017 and 2018. All cohorts were approved by the ethics committee of the respective hospitals for the procedures of this study.

The two different cohort samples were handled by different pathology laboratories, fixed and embedded by the respective staff. The samples were similarly processed and analyzed at different time points. For the PCZA cohort, three biological replicates (size $1 \times 1 \times 5 \text{ mm}^3$) were collected and analyzed by SWATH MS and MRM-HR. For the PCZB cohort, two biological replicates ($1.5 \times 1.5 \times 5 \text{ mm}^3$) were analyzed by MRM-HR.

Pressure cycling technology (PCT)-assisted peptide extraction from FFPE tissues

About 0.5 mg of FFPE tissue was punched from the samples, weighed and processed for each biological replicate via the FFPE-PCT workflow as described previously (26). Briefly, the tissue punches were first dewaxed by incubating with 1 mL of heptane under gentle vortexing at 600–800 rpm, followed by serial rehydration using 1 mL of 100%, 90%, and 75% ethanol (General reagent, G73537B, Shanghai, China), respectively. The samples were further incubated with 200 μL of 0.1% formic acid (FA) (Thermo Fisher Scientific, T-27563) at 30 °C for 30 min for acidic hydrolysis. The tissue punches were then transferred into PCT-MicroTubes (Pressure Biosciences Inc., Boston, MA, USA, MT-96) and briefly washed with 100 μL of freshly prepared 0.1 M Tris-HCl (pH 10.0) to remove residual FA. Thereafter, the tissues were incubated with 15 μL of freshly prepared 0.1 M Tris-HCl (pH 10.0) at 95 °C

for 30 min with gentle vortexing at 600 rpm. Samples were immediately cooled to 4 °C after basic hydrolysis.

Following the pretreatment described above, 25 µL of lysis buffer including 6 M urea (Sigma, U1230), 2 M thiourea (Amresco, M226) in 100 mM ammonium bicarbonate (General reagent, G12990A, Shanghai, China), pH 8.5 was added to the PCT-MicroTubes containing tissues. The tissue samples were further subjected to PCT-assisted tissue lysis and protein digestion procedures using the Barocycler NEP2320-45K (Pressure Biosciences Inc., Boston, MA, USA) as described previously (27). The PCT scheme for tissue lysis was set with each cycle containing a period of 30 s of high pressure at 45 kpsi and 10 s at ambient pressure, oscillating for 90 cycles at 30°C. Protein reduction and alkylation was performed at ambient pressure by incubating protein extracts with 10 mM Tris(2-carboxyethyl) phosphine (TCEP) (Sigma, C4706) and 20 mM iodoacetamide (IAA) (Sigma, I6125) in darkness at 25 °C for 30 min, with gentle vortexing at 600 rpm in a thermomixer. Then the proteins were digested with MS grade Lys-C (Hualishi, Beijing, China, enzyme-to-substrate ratio, 1:40) using a PCT scheme with 50 s of high pressure at 20 kpsi and 10 s of ambient pressure for each cycle, oscillating for 45 cycles at 30 °C. Thereafter, the proteins were further digested with MS grade trypsin (Hualishi, Beijing, China, enzyme-to-substrate ratio, 1:50) using a PCT scheme with 50 s of high pressure at 20 kpsi and 10 s of ambient pressure in one cycle, oscillating for 90 cycles at 30 °C. Peptide digests were then acidified with 1% trifluoroacetic (TFA) (Thermo Fisher Scientific, T/3258/PB05) to pH 2–3 and subjected to C18 desalting. iRT peptides were spiked into peptide samples at a final concentration of 10% prior to MS analysis for RT calibration.

Optimization of microflow LC gradients coupled with SWATH MS

During the optimization studies, 1 µg peptides were separated with different microflow gradients and different SWATH MS parameters. Linear gradients of 3–35% acetonitrile (0.1% formic acid) with durations of 5, 10, 20, 30, and 45 min were evaluated. The number of Q1 variable windows (40, 60, 100) and MS/MS accumulation times (15, 25 ms) constituted the key parameters that were adjusted for the shorter gradients. The need for collision energy spread with the optimized collision energy ramps was tested. Four replicates were performed for each test, after which the data were processed with the PeakView® software with the SWATH 2.0 MicroApp to evaluate the number of proteins and peptides quantified with FDR < 1 % and CV < 20%. The optimized methods were then tested on multiple instruments with different cell lysates to confirm the robustness of the method.

SWATH MS acquisition

Peptides were separated at a flow rate of 5 µL/min by a 15-min SWATH of 5–35% linear LC gradient elution (buffer A: 2% ACN (Sigma, 34851), 0.1% formic acid; buffer B: 80% ACN, 0.1% formic acid) on a column, 3 µm, ChromXP C18CL, 120 Å, 150 x 0.3 mm using an Eksigent NanoLC™ 400 System coupled with a TripleTOF® 6600 system (SCIEX). The DuoSpray Source was replumbed using the 25 µm ID hybrid electrodes to minimize post-column dead volume. The applied SWATH method was composed of a 150 ms TOF MS scan with m/z ranging from 350 to 1250 Da, followed by MS/MS scans performed on all precursors (from 100 to 1500 Da) in a cyclic manner. A 100 variable Q1 isolation window scheme was used in this study (Supplementary Table 1B). The accumulation time was set at 25 ms per isolation window, resulting in a total cycle time of 2.7 s.

We also included beta-galactosidase digest (β-gal) (SCIEX, 4465867) for mass and retention time calibration which was analyzed every four injections. The target ion (m/z = 729.4) which is from a peptide precursor in the β-gal digest mixture was monitored under high sensitivity mode. The RT, intensity, and m/z of targeted precursor and fragment ions were respectively used for LC QC, the sensitivity test, and mass calibration separately.

MRM-HR MS acquisition

A time scheduled MRM-HR targeted quantification strategy was used to further validate proteins observed to be differentially expressed proteins by SWATH MS as described above. The same microflow LC approach was used for 15-min SWATH MS analysis. The TripleTOF 6600 mass spectrometer was operated in IDA mode for time-scheduling the MS/MS acquisition for 134 peptides for the MRM-HR workflow. The method consisted of one 75 ms TOF-MS scan for precursor ions with m/z ranging from 350 to 1250 Da, followed by MS/MS scans for fragment ions with m/z ranging from 100 to 1500 Da, allowing for a maximum of 45 candidate ions being monitored per cycle (25 ms accumulation time, 50 ppm mass tolerance, rolling collision energy, +2 to +5 charge states with intensity criteria above 2 000 000 cps to guarantee that no untargeted peptides should be acquired). The fragment ion information including m/z and RT of a targeted precursor ion was confirmed by previous SWATH results and was then added to the inclusion list for the targeted analysis. The intensity threshold of targeted precursors in the inclusion list was set to 0 cps and the scheduling window was 60 s. The targeted peptide sequences were the same as those found in the previous SWATH MS analysis.

Targeted MRM-HR data were analyzed by 19.0.9.149 Skyline (28), which automatically detected the extracted-ion chromatogram (XIC) from an LC run by matching the MS spectra of the targeted ion against its spectral library generated from the IDA mode within a specific mass tolerance window around its m/z . All peaks selected were checked manually after automated peak detection using Skyline. Both MS1 and MS2 filtering were set as “TOF mass analyzer” with a resolution power of 30 000 and 15 000, respectively, while the “Targeted” acquisition method was defined in the MS/MS filtering.

SWATH data analysis

The optimization data for optimal LC gradients were processed using the SWATH 2.0 MicroApp in PeakView® software (SCIEX) using the pan-human library (29). RT calibration was performed by first using iRT peptides with RT window at a 75 ppm XIC extraction width. Replicate analysis was performed using the SWATH Replicate Analysis Template (SCIEX) to determine the number of peptides and proteins quantified with FDR < 1% peptide and CV < 10 or 20%.

The data from prostate samples were processed using the OpenSWATH pipeline. Briefly, SWATH raw data files were converted in profile mode to mzXML using msconvert and analyzed using OpenSWATH (2.0.0) (30) as described previously (15). The retention time extraction window was 600 s, while m/z extraction was performed with 0.03 Da tolerance. RT was then calibrated using both iRT peptides. Peptide precursors were identified by OpenSWATH and PyProphet (2.0.1) with d_score < 0.01 and FDR < 1%. For each protein, the median MS2 intensity value of peptide precursor fragments which were detected to belong to the protein was used to represent the protein abundance.

RESULTS AND DISCUSSIONS

Establishment and optimization of the 15-min microflow SWATH MS method

A HEK 293 cell lysate digest was used to establish and optimize the short microflow LC gradient and SWATH acquisition schemes on TripleTOF 6600 systems. Specifically, we tested the effects of LC gradient lengths of 5, 10, 20, and 45 min, and mass spectrometer parameters including variable Q1 windows and accumulation time for MS2 (Supplementary Table 1). For each injection 1 μ g mass of total peptide was loaded onto a microflow column of 150 x 0.3 mm dimensions and analyzed under a range of conditions. To increase robustness of results, four technical replicates of each condition were used. The acquired data were searched consistently searched against PHL with the PeakView® software and the SWATH 2.0 MicroApp and the number of peptides and inferred proteins, as well as their intensities were recorded. The data was processed as described in the methods section and evaluated

according to the number of proteins and peptides identified with $FDR < 1\%$ and quantified with $CV < 10\%$ or $CV < 20\%$, respectively. The whole dataset was acquired on two different instruments. Supplementary Figure 1a shows that using shorter gradient methods generated similar results between the two different 6600 instruments. Our data also showed that the 20 min microflow method detected 90% of the proteins quantified by 45 min method, while the 10 min LC method identified 70% of the proteins. With decreasing gradient length, the number of identified proteins further decreased to 77% for a 10 min method to 53% for a 5 min method in their best condition (Supplementary Figure 1a).

Next, we optimized the specific mass spec parameters including variable windows and accumulation times to balance the width of the windows and scan times (Supplementary Figure 1b). Typically, more variable windows led to more peptides and proteins quantified robustly, but only up to a point where the MS/MS acquisition rates become too fast or the cycle times too long, as evidenced in the 5min gradient optimization results. Thus, a higher number of variable windows led to a higher number of peptide and protein identifications. The optimal accumulation time was highly dependent on the LC time. Higher numbers of acquisition windows necessitated shorter MS/MS accumulation times per precursor ion window to maintain a cycle time that was compatible with the peak width generated by the respective gradients. Considering the tradeoff between sample throughput and numbers of proteins quantified, the gradient time from 10 min to 20 min is a better choice according to the efficiency of peptides and proteins identification in unit of time (Supplementary Figure 1b). Therefore, we chose the 15 min gradient as the optimal LC condition (Supplementary Figure 2).

Application of short gradient microflow-SWATH to a PCa patient cohort

We evaluated the performance of the optimized short gradient microflow LC SWATH method on a set of prostate cancer (PCa) tissue samples named PCZA. The set consisted of 204 FFPE biospecimens collected from 58 PCa patients and 10 benign hyperplasia (BPH) patients (Supplementary Table 2) for which clinical data were also available. The 204 samples were randomly divided into seven batches and digested into peptides in barocyclers. Every batch included a mouse liver sample as quality control (QC) for the PCT-assisted sample preparation and a prostate tissue pool samples as the QC sample for SWATH MS (Supplementary Figure 3).

We then subjected the resulting peptide samples to the 15-min-SWATH method optimized above (Figure 1a). The total sample set consisted of 58 PCa samples and 7 QC and reference samples. The 204 samples were measured in 125.7 hrs (~5 days) and quantified 27,975 peptide precursors from 4,038 SwissProt proteins (without protein grouping) with 74.79% missing value rate. On average, 5,615 peptide precursors from 1,018 proteins were quantified for each sample. More peptides and proteins were quantified from tumor samples (5,861 peptide precursors from 1,078 proteins on average) than benign samples (3,988 peptide precursors from 618 proteins on average). Totally 913 proteins were quantified in at least 50% samples (Supplementary Table 3).

To allow a comparison of the accelerated short gradient method with a standard SWATH MS method with respect to the number of proteins recorded and the respective clinically relevant information content we re-acquired the whole sample set with a 120-min LC gradient and 48 variable Q1 windows in a TripleTOF 5600+(26). These measurements consumed 467 hr (~20 days) and identified 38,338 peptide precursors from 5,059 SwissProt proteins with 61.86% missing value rate. On average, 10,751 peptide precursors from 1,921 proteins were quantified for each sample. More peptides and proteins were quantified from tumor samples (11,439 peptide precursors from 2,054 proteins on average) than benign samples (6,693 peptide precursors from 1192 proteins on average). Totally 1,914 proteins were quantified in at least 50% samples (Supplementary Table 3). Compare to this 120-min method, the 15-min method characterized about half of peptide precursors and proteins.

Overall, the data shows that the 15-min-SWATH coverage reached 50-80% of that achieved by a standard method. In all samples, 3,800 proteins were quantified by both methods. This result was generated at a 6-fold reduced acquisition time (time 125.7 hrs vs, 467 hrs) (Figure 1b) suggesting that clinical cohorts of significant size can be measured by the accelerated method quickly, efficiently.

Reproducibility and batch effect analysis

We evaluated the reproducibility of the datasets produced by the 15-min gradient and the 120-min gradient SWATH with respect to reproducibility and batch effect. We first assessed the technical reproducibility by correlation between technical replicates for LC-MS. The technical reproducibility of the data obtained by the 15-min SWATH method ($r = 0.99$) is slightly higher than that from the 120-min SWATH method ($r = 0.86$) (Figure 2a). Thus, the measured biological reproducibility is also slightly higher in the 15-min SWATH method (Figure 2a). If we focused the analysis on the 3,800 proteins quantified by both methods, we observed a high degree of similarity ($r = 0.7681$) between the methods (Figure 2b).

We next analyzed batch effects apparent in either dataset. Batch effects are an unavoidable reality resulting from technical variation in multi-day MS analyses and are a non-trivial complication for big cohort proteomics analysis. Several algorithms have been developed to bioinformatically minimize the missing value rate, however, these imputation approaches remain controversial (31). We evaluated the batch effect of the data acquired by the 15-min SWATH, which is lower than that from the 120-min method (Figure 2c). Together, the 15-min SWATH method improved quantitative reproducibility and reduced batch effect.

Verification of differential expression proteins using MRM-HR

On the path to clinical or preclinical use protein biomarkers detected by MS based cohort studies face a number of verification and validation requirements. These include technical verification of the abundance changes detected in the cohort study and validation in independent sample cohorts.

To further validation the abundance changes detected in the SWATH data we selected a panel of 75 proteins showing different abundance (absolute fold change larger than two and adjusted p-value less than 0.05) between control and tumor tissue and measured their respective intensities using the targeted MS method MRM-HR. The selected proteins were associated with most strongly cancer dis regulated pathways and included 21 known diagnosis biomarkers such as ACPP and FASN, and 10 drug targets (Supplementary Table 4A). The proteins were further annotated in IPA (Supplementary Table 4B) indicating that the proteins suggested elevated cell migration, development and growth, and suppressed cell death and survival (Supplementary Figure 5).

For these measurements the MRM-HR method was optimized using a pooled prostate sample to determine the best performing peptides from the selected proteins, and best target fragment ions for quantitation. The information about proteins and peptides including the RTs was imported into Skyline to build a spectral library. A total of 134 peptides for 75 proteins were selected for targeted detection (Supplementary Table 2E). Time scheduling was used to ensure at least eight data points were obtained across the LC peaks as well as an optimized accumulation time of 25 ms for each peptide for high-quality quantitative data.

To confirm the quantitative accuracy of the 15-min SWATH data, we re-analyzed 99 samples in the PCZA cohort using the MRM-HR method. The 99 samples were randomly allocated to five batches, each containing 20 samples and an extra MS QC sample which was a pool of prostate tissue digests in PCZA. We firstly examined the reproducibility of XICs for all peptides in MRM-HR assays. For the five pooled samples measured across five batches, we found that 76.6% of precursors measured from the peptides were quantified with a CV below 20%. The median CV was 13.4% (Supplementary Figure 6). Next the protein fold-changes between tumor and normal samples were calculated to investigate the

correlation of 15-min SWATH with MRM-HR (Figure 3a).

We further quantified the expression levels of the 75-protein-panel in an independent prostate cancer cohort, PCZB, containing 30 BPH and 24 PCa in duplicated biological replicates using the same 15-min SWATH MRM-HR workflow (Supplementary Table 5). For the six pooled samples measured across six batches, 75.6% of peptide precursors were quantified with a CV below 20%. The median CV is 14.9% (Supplementary Figure 6).

To assess the power of the protein panel of differentially abundant proteins to separate benign and malignant tissues, we assembled a random-forest model for the PCZA MRM-HR dataset, and found an accuracy of 0.992 in this set (Supplementary Figure 7). Next, we tested the ability of this panel to separate tumor from benign prostatic tissue samples in an independent patient group, *i.e.* PCZB, including 24 PCa patients and 30 BPH patients. The receiver operating curves (ROC) of the 75-protein-panel clearly distinguished PCa from BPH patient groups (Figure 3b).

We then investigated in detail two proteins—PRDX3 (P30048) and COPA (P53621) which were prioritized because of their role in TP53 oncogene regulation and as a potential drug (decitabine) target (Supplementary Figure 8). The data show that these proteins significantly up-regulated in tumor tissue from all three workflows, *i.e.* 15-min-SWATH, and MRM-HR in the PCZA cohort samples and MRM-HR in the PCZB cohort (Figure 3b). The ROC curve of these two proteins from three different datasets distinguishing benign from malignant tissue samples are shown in Supplementary Figure 9, with all of AUC over 0.78. Taken together, we validated these dysregulated proteins quantification by SWATH showed higher reliability and performed better prediction ability in different sample cohorts.

380

381 Conclusion

In this study, we present a 15-min microflow-LC SWATH that supports the consistent proteomic analysis of clinical (FFPE) samples at a throughput of ~50 samples per day (excluding calibration and washing). The method is therefore well suited for the analysis of large sample cohorts, even in a single investigator proteomic laboratory. The results show that the presented method increases the throughput by ca six-fold compared to a conventional SWATH MS method, at reduced batch effects and at an attrition of ca 20% of detected proteins and increased missing value rate (~20% worse) in the prostate cancer cohort. For individual samples, the number of detected proteins decreased by ~50%. The quantitative accuracy of the short gradient method was comparable to that achieved by targeted quantification using MRM-HR for shortlisted proteins. This work showed the potential of this short gradient SWATH proteomics pipeline for accelerated discovery and verification of protein biomarkers for precision medicine.

394 Author Contributions

T.G., C.H., R.S. designed the project. C.H., N.M. and C.C. optimized the 15-min-SWATH. X.Y., L.C. procured the three prostate cohorts. R.S. performed the PCT SWATH analysis with help from X.C. C.C. and R.S. performed the MRM-HR analysis. W.G., R.S., S.D., analyzed the data. R.S., Y.Z., C.H., R.A. and T.G. wrote the manuscript. Z.L assisted data analysis. S.L., C.Y. gave valuable advice. T.G., Y.Z. supported and supervised the project.

400

Research Funding: Zhejiang Provincial Natural Science Foundation of China (Grant No. LR19C050001 to T.G.). Hangzhou Agriculture and Society Advancement Program (Grant No. 20190101A04 to T.G.). National Natural Science Foundation of China (General Program) (Grant No. 81972492 to T.G.). National Science Fund for Young Scholars (Grant No. 21904107).

406

407 **Acknowledgments:** We thank Dr Xuan Ding for review of the manuscript.

408 **Competing financial interests:** The research group of T.G. is partly supported by SCIEEX,
409 which provides access to prototype instrumentation, and Pressure Biosciences Inc, which
410 provides access to advanced sample preparation instrumentation.

411
412 **Data and materials availability:** The 15-min SWATH data are deposited in PRIDE. Project
413 accession: IPX0001645000. The 15-min SWATH data are deposited in iProX
414 (IPX0001645001). The MRM-HR data are deposited in iProX (IPX0001645002). All the data
415 will be publicly released upon publication.

416

417 **ABBREVIATIONS**

418 AUC = area under the curve
419 BPH = benign prostatic hyperplasia
420 CV = coefficient of variation
421 DDA = data dependent acquisition
422 DIA = data independent acquisition
423 FA = formic acid
424 FDR = false discovery rate
425 FFPE = formalin fixed, paraffin embedded
426 IAA = iodoacetamide
427 IPA = ingenuity pathway analysis
428 LC = liquid chromatograph
429 MRM-HR = multiple reaction monitoring high-resolution
430 PCa = prostate cancer
431 PCT = pressure cycling technology
432 PRM = parallel reaction monitoring
433 QC = quality control
434 ROC = receiver operating characteristic
435 RF = random forest
436 RT = retention time
437 SWATH MS = sequential windowed acquisition of all theoretical fragment ion - mass spectra
438 TCEP = tris(2-carboxyethyl) phosphine TFA = trifluoroacetic
439 TMA = tissue microarray analysis
440 TOF = time of flight
441 XIC = extracted ion chromatogram

442

443 **References**

- 444 1. Olsen, M.; Ghannad, M.; Lok, C.; Bossuyt, P. M., Shortcomings in the evaluation of
445 biomarkers in ovarian cancer: a systematic review. *Clin Chem Lab Med* **2019**.
- 446 2. Rifai, N.; Gillette, M. A.; Carr, S. A., Protein biomarker discovery and validation: the long
447 and uncertain path to clinical utility. *Nat Biotechnol* **2006**, 24, (8), 971-83.

- 448 3. Anderson, N. L.; Ptolemy, A. S.; Rifai, N., The riddle of protein diagnostics: future bleak or
449 bright? *Clin Chem* **2013**, 59, (1), 194-7.
- 450 4. Frantzi, M.; Latosinska, A.; Kontostathi, G.; Mischak, H., Clinical Proteomics: Closing the
451 Gap from Discovery to Implementation. *Proteomics* **2018**, 18, (14), e1700463.
- 452 5. Liu, Y.; Buil, A.; Collins, B. C.; Gillet, L. C.; Blum, L. C.; Cheng, L. Y.; Vitek, O.; Mouritsen,
453 J.; Lachance, G.; Spector, T. D.; Dermitzakis, E. T.; Aebersold, R., Quantitative variability of
454 342 plasma proteins in a human twin population. *Mol Syst Biol* **2015**, 11, (1), 786.
- 455 6. Aebersold, R.; Mann, M., Mass-spectrometric exploration of proteome structure and
456 function. *Nature* **2016**, 537, (7620), 347-55.
- 457 7. Sabrkhany, S.; Kuijpers, M. J. E.; Knol, J. C.; Olde Damink, S. W. M.; Dingemans, A. C.;
458 Verheul, H. M.; Piersma, S. R.; Pham, T. V.; Griffioen, A. W.; Oude Egbrink, M. G. A.; Jimenez,
459 C. R., Exploration of the platelet proteome in patients with early-stage cancer. *J Proteomics*
460 **2018**, 177, 65-74.
- 461 8. Mun, D. G.; Bhin, J.; Kim, S.; Kim, H.; Jung, J. H.; Jung, Y.; Jang, Y. E.; Park, J. M.; Kim,
462 H.; Jung, Y.; Lee, H.; Bae, J.; Back, S.; Kim, S. J.; Kim, J.; Park, H.; Li, H.; Hwang, K. B.; Park,
463 Y. S.; Yook, J. H.; Kim, B. S.; Kwon, S. Y.; Ryu, S. W.; Park, D. Y.; Jeon, T. Y.; Kim, D. H.; Lee,
464 J. H.; Han, S. U.; Song, K. S.; Park, D.; Park, J. W.; Rodriguez, H.; Kim, J.; Lee, H.; Kim, K. P.;
465 Yang, E. G.; Kim, H. K.; Paek, E.; Lee, S.; Lee, S. W.; Hwang, D., Proteogenomic
466 Characterization of Human Early-Onset Gastric Cancer. *Cancer Cell* **2019**, 35, (1), 111-124
467 e10.
- 468 9. Zhang, H.; Liu, T.; Zhang, Z.; Payne, S. H.; Zhang, B.; McDermott, J. E.; Zhou, J. Y.;
469 Petyuk, V. A.; Chen, L.; Ray, D.; Sun, S.; Yang, F.; Chen, L.; Wang, J.; Shah, P.; Cha, S. W.;

470 Aiyetan, P.; Woo, S.; Tian, Y.; Gritsenko, M. A.; Clauss, T. R.; Choi, C.; Monroe, M. E.;
471 Thomas, S.; Nie, S.; Wu, C.; Moore, R. J.; Yu, K. H.; Tabb, D. L.; Fenyo, D.; Bafna, V.; Wang,
472 Y.; Rodriguez, H.; Boja, E. S.; Hiltke, T.; Rivers, R. C.; Sokoll, L.; Zhu, H.; Shih, I. M.; Cope, L.;
473 Pandey, A.; Zhang, B.; Snyder, M. P.; Levine, D. A.; Smith, R. D.; Chan, D. W.; Rodland, K. D.;
474 Investigators, C., Integrated Proteogenomic Characterization of Human High-Grade Serous
475 Ovarian Cancer. *Cell***2016**, 166, (3), 755-765.

476 10. Vasaikar, S.; Huang, C.; Wang, X.; Petyuk, V. A.; Savage, S. R.; Wen, B.; Dou, Y.; Zhang,
477 Y.; Shi, Z.; Arshad, O. A.; Gritsenko, M. A.; Zimmerman, L. J.; McDermott, J. E.; Clauss, T. R.;
478 Moore, R. J.; Zhao, R.; Monroe, M. E.; Wang, Y. T.; Chambers, M. C.; Slebos, R. J. C.; Lau, K.
479 S.; Mo, Q.; Ding, L.; Ellis, M.; Thiagarajan, M.; Kinsinger, C. R.; Rodriguez, H.; Smith, R. D.;
480 Rodland, K. D.; Liebler, D. C.; Liu, T.; Zhang, B.; Clinical Proteomic Tumor Analysis, C.,
481 Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities.
482 *Cell***2019**, 177, (4), 1035-1049 e19.

483 11. Mertins, P.; Mani, D. R.; Ruggles, K. V.; Gillette, M. A.; Clauser, K. R.; Wang, P.; Wang,
484 X.; Qiao, J. W.; Cao, S.; Petralia, F.; Kawaler, E.; Mundt, F.; Krug, K.; Tu, Z.; Lei, J. T.; Gatza,
485 M. L.; Wilkerson, M.; Perou, C. M.; Yellapantula, V.; Huang, K. L.; Lin, C.; McLellan, M. D.; Yan,
486 P.; Davies, S. R.; Townsend, R. R.; Skates, S. J.; Wang, J.; Zhang, B.; Kinsinger, C. R.; Mesri,
487 M.; Rodriguez, H.; Ding, L.; Paulovich, A. G.; Fenyo, D.; Ellis, M. J.; Carr, S. A.; Nci, C.,
488 Proteogenomics connects somatic mutations to signalling in breast cancer. *Nature***2016**, 534,
489 (7605), 55-62.

490 12. Thomas, S.; Friedrich, B.; Schnaubelt, M.; Chan, D.; Zhang, H.; Aebersold, R.,
491 Orthogonal proteomic platforms and their implications for the stable classification of

- 492 high-grade serous ovarian cancer subtypes. *BioRxiv* **2019**.
- 493 13. Bekker-Jensen, D. B.; Kelstrup, C. D.; Batth, T. S.; Larsen, S. C.; Haldrup, C.; Bramsen, J.
494 B.; Sorensen, K. D.; Hoyer, S.; Orntoft, T. F.; Andersen, C. L.; Nielsen, M. L.; Olsen, J. V., An
495 Optimized Shotgun Strategy for the Rapid Generation of Comprehensive Human Proteomes.
496 *Cell Syst* **2017**, 4, (6), 587-599 e4.
- 497 14. Gillet LC, N. P., Tate S, Röst H, Selevsek N, Reiter L, Bonner R, Aebersold R., Targeted
498 data extraction of the MS/MS spectra generated by data-independent acquisition: a new
499 concept for consistent and accurate proteome analysis. *Mol Cell Proteomics*. **2012**.
- 500 15. Guo, T.; Kouvonen, P.; Koh, C. C.; Gillet, L. C.; Wolski, W. E.; Rost, H. L.; Rosenberger,
501 G.; Collins, B. C.; Blum, L. C.; Gillessen, S.; Joerger, M.; Jochum, W.; Aebersold, R., Rapid
502 mass spectrometric conversion of tissue biopsy samples into permanent quantitative digital
503 proteome maps. *Nat Med* **2015**, 21, (4), 407-13.
- 504 16. Bouchal, P.; Schubert, O. T.; Faktor, J.; Capkova, L.; Imrichova, H.; Zoufalova, K.;
505 Paralova, V.; Hrstka, R.; Liu, Y.; Ebhardt, H. A.; Budinska, E.; Nenutil, R.; Aebersold, R.,
506 Breast Cancer Classification Based on Proteotypes Obtained by SWATH Mass Spectrometry.
507 *Cell Rep* **2019**, 28, (3), 832-843 e7.
- 508 17. Zhu, Y.; Zhu, J.; Lu, C.; Zhang, Q.; Xie, W.; Sun, P.; Dong, X.; Yue, L.; Sun, Y.; Yi, X.; Zhu,
509 T.; Ruan, G.; Aebersold, R.; Huang, S.; Guo, T., Identification of Protein Abundance Changes
510 in Hepatocellular Carcinoma Tissues Using PCT-SWATH. *Proteomics Clin Appl* **2019**, 13, (1),
511 e1700179.
- 512 18. Guo, T.; Li, L.; Zhong, Q.; Rupp, N. J.; Champi, K.; Wong, C. E.; Wagner, U.; Rueschoff,
513 J. H.; Jochum, W.; Fankhauser, C. D.; Saba, K.; Poyet, C.; Wild, P. J.; Aebersold, R.; Beyer, A.,

514 Multi-region proteome analysis quantifies spatial heterogeneity of prostate tissue biomarkers.
515 *Life Sci Alliance* **2018**, 1, (2).

516 19. Bache N1, G. P., 3, Bekker-Jensen DB3, Hoerning O1, Falkenby L1, Treit PV2, Doll S2,
517 Paron I2, Müller JB2, Meier F2, Olsen JV3, Vorm O1, Mann M, A Novel LC System Embeds
518 Analytes in Pre-formed Gradients for Rapid, Ultra-robust Proteomics. *Mol Cell Proteomics*.
519 **2018**.

520 20. Shi, J.; Wang, X.; Lyu, L.; Jiang, H.; Zhu, H. J., Comparison of protein expression
521 between human livers and the hepatic cell lines HepG2, Hep3B, and Huh7 using SWATH and
522 MRM-HR proteomics: Focusing on drug-metabolizing enzymes. *Drug Metab Pharmacokinet*
523 **2018**, 33, (2), 133-140.

524 21. He, B.; Shi, J.; Wang, X.; Jiang, H.; Zhu, H. J., Label-free absolute protein quantification
525 with data-independent acquisition. *J Proteomics* **2019**, 200, 51-59.

526 22. Colgrave, M. L.; Byrne, K.; Blundell, M.; Heidelberger, S.; Lane, C. S.; Tanner, G. J.;
527 Howitt, C. A., Comparing Multiple Reaction Monitoring and Sequential Window Acquisition of
528 All Theoretical Mass Spectra for the Relative Quantification of Barley Gluten in Selectively
529 Bred Barley Lines. *Anal Chem* **2016**, 88, (18), 9127-35.

530 23. Le Duff, M.; Gouju, J.; Jonchere, B.; Guillon, J.; Toutain, B.; Boissard, A.; Henry, C.;
531 Guette, C.; Lelievre, E.; Coqueret, O., Regulation of senescence escape by the
532 cdk4-EZH2-AP2M1 pathway in response to chemotherapy. *Cell Death Dis* **2018**, 9, (2), 199.

533 24. Vowinckel, J.; Zelezniak, A.; Bruderer, R.; Mulleder, M.; Reiter, L.; Ralser, M.,
534 Cost-effective generation of precise label-free quantitative proteomes in high-throughput by
535 microLC and data-independent acquisition. *Sci Rep* **2018**, 8, (1), 4346.

- 536 25. Liu, Y.; Mi, Y.; Mueller, T.; Kreibich, S.; Williams, E. G.; Van Drogen, A.; Borel, C.; Frank,
537 M.; Germain, P. L.; Bludau, I.; Mehnert, M.; Seifert, M.; Emmenlauer, M.; Sorg, I.; Bezrukov, F.;
538 Bena, F. S.; Zhou, H.; Dehio, C.; Testa, G.; Saez-Rodriguez, J.; Antonarakis, S. E.; Hardt, W.
539 D.; Aebersold, R., Multi-omic measurements of heterogeneity in HeLa cells across laboratories.
540 *Nat Biotechnol* **2019**, 37, (3), 314-322.
- 541 26. Yi Zhu 1, 3*, Tobias Weiss 4*, Qiushi Zhang 1,2, Rui Sun 1,2, Bo Wang 5, Zhicheng Wu
542 1,2, Qing Zhong 6,7, Xiao Yi 1,2, Huanhuan Gao 1,2, Xue Cai 1,2, Guan Ruan 1,2, Tiansheng
543 Zhu 1,2, Chao Xu, Sai Lou 9, Xiaoyan Yu 10, Ludovic Gillet 3, Peter Blattmann 3, Karim Saba
544 11, Christian D.Fankhauser 11, Michael B. Schmid 11, Dorothea Rutishauser 6, Jelena
545 Ljubicic 6, Ailsa, Christiansen 6, Christine Fritz 6, Niels J. Rupp 6, Cedric Poyet 11, Elisabeth
546 Rushing 12, Michael Weller 4, Patrick Roth 4, Eugenia Haralambieva 6, Silvia Hofer 13, Chen
547 Chen 14, Wolfram Jochum 15, Xiaofei Gao 1,2, Xiaodong Teng 5, Lirong Chen 10, Peter J.
548 Wild 6,16#, Ruedi Aebersold 3,17#, Tiannan Guo, High-throughput proteomic analysis of
549 FFPE tissue samples facilitates tumor stratification. *bioRxiv* **2019**.
- 550 27. Zhu, Y.; Guo, T., High-Throughput Proteomic Analysis of Fresh-Frozen Biopsy Tissue
551 Samples Using Pressure Cycling Technology Coupled with SWATH Mass Spectrometry.
552 *Methods Mol Biol* **2018**, 1788, 279-287.
- 553 28. MacLean, B.; Tomazela, D. M.; Shulman, N.; Chambers, M.; Finney, G. L.; Frewen, B.;
554 Kern, R.; Tabb, D. L.; Liebler, D. C.; MacCoss, M. J., Skyline: an open source document editor
555 for creating and analyzing targeted proteomics experiments. *Bioinformatics* **2010**, 26, (7),
556 966-8.
- 557 29. Rosenberger, G.; Koh, C. C.; Guo, T.; Rost, H. L.; Kouvonen, P.; Collins, B. C.; Heusel,

558 M.; Liu, Y.; Caron, E.; Vichalkovski, A.; Faini, M.; Schubert, O. T.; Faridi, P.; Ebhardt, H. A.;
559 Matondo, M.; Lam, H.; Bader, S. L.; Campbell, D. S.; Deutsch, E. W.; Moritz, R. L.; Tate, S.;
560 Aebersold, R., A repository of assays to quantify 10,000 human proteins by SWATH-MS. *Sci*
561 *Data* **2014**, 1, 140031.

562 30. Rost, H. L.; Rosenberger, G.; Navarro, P.; Gillet, L.; Miladinovic, S. M.; Schubert, O. T.;
563 Wolski, W.; Collins, B. C.; Malmstrom, J.; Malmstrom, L.; Aebersold, R., OpenSWATH enables
564 automated, targeted analysis of data-independent acquisition MS data. *Nat Biotechnol* **2014**,
565 32, (3), 219-23.

566 31. Goh, W. W. B.; Wong, L., Advanced bioinformatics methods for practical applications in
567 proteomics. *Brief Bioinform* **2019**, 20, (1), 347-355.

568

569

Figure 1. The short-gradient SWATH method and application in the PCZA PCa cohort. (a) Comparison of parameters between the 15-min SWATH and 120-min SWATH methods. (b) The workflow of the 15-min-SWATH and conventional SWATH for the PCZA cohort. We designed seven randomly shuffled batches with a column washing run and a calibration (β -gal) run inserted every four samples.

Figure 2. The reproducibility of the short gradient SWATH method in the PCZA PCa cohort. (a) Violin plots show the technical replicates and biological replicates in the two methods. (b) Pearson correlation of log₂-scaled protein intensity values obtained from 3,800 proteins that were quantified by both methods. (c) PCA analysis of all samples quantified by the 120-min method (left) and the 15-min method (right).

Figure 3. Verification of proteomic data using MRM-HR. (a) Pearson correlation coefficient between the 15-min SWATH and MRM-HR datasets based on the $\log_2(T/N)$ of protein expression in PCZA. (b) The ROC curves of protein quantification from MRM-HR to predict the tumor and normal tissues with the random forest algorithm in PCZB (T: PCa, N: BPH, H: hyperplasia in BPH patients, B: benign in BPH patients). (c) MRM-HR validation of potential diagnostic proteins using the PCZA and PCZB. PRDX3 (peptide: +2 DYGVLLGSGGLALR), COPA (peptide: +2 DVAVMQLR). The left panel shows the fragment ion extracted-ion chromatograms (XICs) for the peptide from each protein. The right panel of boxplots shows the peptides quantified in the different data sets.